



United We Stand

Bi-Coastal Pharmaceutical Corp.®

Sales, Marketing, Consulting



Press Release

CONTACT:

Gary Frank
Investor Relations Services, Inc.
(904) 409-0200

Source: Able Laboratories, INC.
Date: Mar 30 2001

Dynagen Enters Sales Agreement with Bi-Coastal Pharmaceutical

Agreement provides for selling current and future products in the generic distributor, private label, managed care and mail order markets

South Plainfield, NJ, March 30, 2001 – DYNAGEN, INC. (OTC BB: DYGN)

(BSE: DYGN) today announced its wholly owned subsidiary, Able Laboratories, has entered a three-year distribution agreement with Bi-Coastal Pharmaceutical Corporation. Under the terms of the contract, Bi-Coastal will sell Able Laboratories current and future generic drug products into four major U.S. markets including generic distributors, several private labels, managed care and mail order.

"Bi-Coastal will assist us in getting our products out to a diverse number of markets," commented C. Robert Cusick, Chairman and Chief Executive Officer of DynaGen. "Bi-Coastal has a proven track record of producing and supporting major sales growth. They have a highly experience sales force that will not only assist us with increased sales of our existing products but will provide excellent exposure for our new products that should soon be receiving FDA approval."

"I am pleased to add Able Laboratories to the growing list of manufacturers that we represent in the pharmaceutical marketplace," stated Ralph Massa, Jr., Bi-Coastal's Chief Operating Officer. "We look forward to increasing Able's sales and name recognition with our accounts that have had little exposure to the Company's products in the past."

Founded in 1982, BI-Coastal Pharmaceutical Corporation is a leading sales, marketing and consulting company in the generic pharmaceutical industry with annual sales in excess of \$100 million.



United We Stand

Bi-Coastal Pharmaceutical Corp.®

Sales, Marketing, Consulting



Press Release

CONTACT:

Gary Frank
Investor Relations Services, Inc.
(904) 409-0200

Source: Able Laboratories, INC.

Date: Mar 30 2001

Dynagen Enters Sales Agreement with Bi-Coastal Pharmaceutical

DynaGen, Inc. is a rapidly growing developer and manufacturer of generic pharmaceuticals. The focus of the Company is to develop products that offer attractive market opportunities within selected niche markets of the generic drug industry. In addition to the five products it is currently selling, the Company has fourteen products at various stages of FDA approval. The Company has recently completed its transition from a manufacturing and distribution company into a sole development and manufacturing entity. As part of the Company's commitment to its new strategic focus, the Company will change its name from DynaGen, Inc. to Able Laboratories, Inc. shortly.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release (as well as information included in oral statements or other written statements made or to be made by DynaGen, Inc.) contain statements that are forward-looking, such statements relate to anticipated future revenues of the companies and success of current product offerings. There is no assurance that the company will receive FDA approvals for its new products or achieve the sales levels that will make the operation profitable. Such forward-looking information involves significant risks and uncertainties that could significantly affect anticipated results in the future and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of DynaGen, Inc. For a description of additional risks, and uncertainties, please refer to DynaGen, Inc., filings with the Securities and Exchange Commission, including Forms 10-KSB and 10-QSB.